Drilon A, Cho BC, Camidge DR, Nagasaka M, Besse B, Solomon B, Goto K, Wolf J, Popat S, Felip E, Yang N, de Langen AJ, Lu S, Velcheti V, Lin AL, Calvet CY, Li L, Tschaika M, Afsar S, Yang H, Lin JJ. Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. Oncologist. 2026 May 08; 31(6).